<DOC>
	<DOC>NCT01214122</DOC>
	<brief_summary>The primary purpose of this study is to determine whether the treatment with AZD9668 will affect the metabolism and effect of Warfarin.</brief_summary>
	<brief_title>A Drug-Drug Interaction Study Between AZD9668 and Warfarin to Study the Effect of AZD9668 on the Metabolism and Effect of Warfarin</brief_title>
	<detailed_description />
	<mesh_term>Warfarin</mesh_term>
	<criteria>Provision of signed informed consent (including genotyping screening sample for CYP2C9 and VKORC1) prior to any study specific procedures Subjects must be willing to use a barrier method of contraception, unless their partners are postmenopausal or surgically sterile, or if a female partner is of childbearing potential the subject must use a barrier method of contraception (condom) and the partner must use accepted contraceptive methods (oral contraceptive, implant, long term injectable contraceptive or intrauterine device), from first dose of IP (warfarin and AZD9668) until 3 months after last dose of IP (warfarin and AZD9668) Have a body mass index between 19 and 30 kg/m2 (inclusive) and a weight between 50 and 100 kg (inclusive) Be a nonsmoker or exsmoker who has stopped smoking for &gt;6 months prior to Visit 1. Any clinically significant disease or disorder Subject predicted to have high sensitivity to warfarin based on CYP2C9 and VKORC1 genotypes Any clinically relevant abnormal findings in physical examination</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Drug-Drug interaction</keyword>
	<keyword>warfarin</keyword>
	<keyword>AZD9668</keyword>
	<keyword>resulting from AZD9668 and Warfarin interaction</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
</DOC>